Kevin Barron – 2016 Parliamentary Question to the Department of Health
The below Parliamentary question was asked by Kevin Barron on 2016-01-13.
To ask the Secretary of State for Health, what plans he has to include generic medicines which are required to have a brand name by the MHRA and are already subject to market competition alongside originator medicines in the Statutory Scheme of Control the Prices of Branded Health Service Medicines.
George Freeman
The Department consulted on options to amend the Statutory Scheme regulations which control the prices of branded health service medicines. Both the voluntary Pharmaceutical Price Regulation Scheme and the statutory scheme include all health service medicines with a brand name, including those required by the Medicines and Healthcare products Regulatory Agency to have a brand name. The Department did not propose any changes to the scope of the statutory scheme in this respect and has not made an estimate of the cost of removing those branded medicines from the statutory scheme.
The Department received responses from a range of organisations including National Health Service, independent bodies and pharmaceutical industry. The Department is currently analysing the responses from a range of organisations including NHS, independent bodies and pharmaceutical industry.
The consultation and impact assessment can be accessed using the following link.
https://www.gov.uk/government/consultations/pricing-of-branded-health-service-medicines
“
